Clinical Trial Update: Rituximab and Belimumab Combination Therapy in PR3 Vasculitis [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating Rituximab and Belimumab combination therapy for ANCA-associated vasculitis, including granulomatosis with polyangiitis.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Anca-associated Vasculitis
• Granulomatosis with Polyangiitis

Drugs mentioned

• Belimumab (belimumab)
• Rituximab (rituximab)

Snippet

Sponsor: Rachel Jones | Conditions: ANCA Associated Vasculitis, Granulomatosis With Polyangiitis | Phase 2 | Status: UNKNOWN